Mostrar el registro sencillo del ítem

dc.contributor.authorXiong, Huizhong
dc.contributor.authorMancini, Maicol
dc.contributor.authorGobert, Michael
dc.contributor.authorShen, Shiqian
dc.contributor.authorFurtado, Glaucia C
dc.contributor.authorLira, Sergio A
dc.contributor.authorParkhurst, Christopher N
dc.contributor.authorGarambois, Veronique
dc.contributor.authorBrengues, Muriel
dc.contributor.authorTadokoro, Carlos E
dc.contributor.authorTrimarchi, Thomas
dc.contributor.authorGómez-López, Gonzalo 
dc.contributor.authorSingh, Amartya
dc.contributor.authorKhiabanian, Hossein
dc.contributor.authorMinuzzo, Sonia
dc.contributor.authorIndraccolo, Stefano
dc.contributor.authorLobry, Camille
dc.contributor.authorAifantis, Iannis
dc.contributor.authorHerranz, Daniel
dc.contributor.authorLafaille, Juan J
dc.contributor.authorMaraver, Antonio
dc.date.accessioned2021-09-01T15:38:36Z
dc.date.available2021-09-01T15:38:36Z
dc.date.issued2021-01-01
dc.identifier.citationTheranostics. 2021 ;11(4):1594-1608.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/13341
dc.description.abstractThe Notch pathway is highly active in almost all patients with T-cell acute lymphoblastic leukemia (T-ALL), but the implication of Notch ligands in T-ALL remains underexplored. Methods: We used a genetic mouse model of Notch ligand delta like 4 (DLL4)-driven T-ALL and performed thymectomies and splenectomies in those animals. We also used several patient-derived T-ALL (PDTALL) models, including one with DLL4 expression on the membrane and we treated PDTALL cells in vitro and in vivo with demcizumab, a blocking antibody against human DLL4 currently being tested in clinical trials in patients with solid cancer. Results: We show that surgical removal of the spleen abrogated T-ALL development in our preclinical DLL4-driven T-ALL mouse model. Mechanistically, we found that the spleen, and not the thymus, promoted the accumulation of circulating CD4+CD8+ T cells before T-ALL onset, suggesting that DLL4-driven T-ALL derives from these cells. Then, we identified a small subset of T-ALL patients showing higher levels of DLL4 expression. Moreover, in mice xenografted with a DLL4-positive PDTALL model, treatment with demcizumab had the same therapeutic effect as global Notch pathway inhibition using the potent γ-secretase inhibitor dibenzazepine. This result demonstrates that, in this PDTALL model, Notch pathway activity depends on DLL4 signaling, thus validating our preclinical mouse model. Conclusion: DLL4 expression in human leukemic cells can be a source of Notch activity in T-ALL, and the spleen plays a major role in a genetic mouse model of DLL4-driven T-ALL.es_ES
dc.description.sponsorshipWe thank Drs. Susan Schwab, Dan Littman, Sherif Ibrahim, Angel Pellicer, Susanne Tranguch and Adolfo Ferrando for helpful discussions and/or critically comments on the manuscript. Elisabetta Andermarcher professionally edited the manuscript. We are indebted to Dr. M. Yan (Genentech) for the anti-DLL4 antibody for cytometry. We are also in debt with Christopher Murriel from Oncomed who provided the therapeutic murine anti-DLL4 antibody and demcizumab (anti-human DLL4 antibody). We thank the NYU School of Medicine Flow Cytometry Core facility, particularly Dr. Peter Lopez, Keith Kobylarz and Michael Gregory, and also the NYU School of Medicine Confocal imaging facility, particularly Yan Deng. We also thank Henry Alexandre Michaud for his great help with the FACS analysis of PDTALL cells. We thank Nelly Pirot and the rest of members of the IRCM IHC platform for their fantastic work. M.M. is supported by a contract from Fondation ARC. The NYU Cancer Institute Center Support Grant partially funded this core through grant NIH/NCI 5 P30CA16087-31. Work in JJL's laboratory is supported by the NIH/NIAID, National Multiple Sclerosis Society, and the Helmsley Charitable Trust. Work in AM's laboratory is supported by the Fondation ARC (PJA 20131200405), the European Commission (CIG631431), the Institute de Cancer de Montpellier Fondation, and the Institut National du Cancer (INCa_9257 and INCa-DGOS-Inserm 12553).es_ES
dc.language.isoenges_ES
dc.publisherIvyspring International Publisher es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshGene Expression Regulation, Neoplastic es_ES
dc.subject.meshAdaptor Proteins, Signal Transducinges_ES
dc.subject.meshAnimals es_ES
dc.subject.meshApoptosis es_ES
dc.subject.meshBiomarkers, Tumor es_ES
dc.subject.meshCalcium-Binding Proteins es_ES
dc.subject.meshCell Proliferation es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMice es_ES
dc.subject.meshMice, Inbred NOD es_ES
dc.subject.meshMice, SCID es_ES
dc.subject.meshPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma es_ES
dc.subject.meshReceptors, Notches_ES
dc.subject.meshSpleen es_ES
dc.subject.meshTumor Cells, Culturedes_ES
dc.subject.meshXenograft Model Antitumor Assays es_ES
dc.titleSpleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID33408769es_ES
dc.format.volume11es_ES
dc.format.number4es_ES
dc.format.page1594-1608es_ES
dc.identifier.doi10.7150/thno.48067es_ES
dc.contributor.funderFondation ARC pour la recherche sur le cancer 
dc.contributor.funderUnited States Department of Health and Human Services 
dc.contributor.funderUnión Europea. Comisión Europea 
dc.contributor.funderFrench National Cancer Institute 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1838-7640es_ES
dc.relation.publisherversionhttps://doi.org/10.7150/thno.48067.es_ES
dc.identifier.journalTheranosticses_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Bioinformáticaes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional